Candel Therapeutics, Inc. - Common Stock, $0.01 par value (CADL)

CUSIP: 137404109

Q1 2026 13F Holders as of 31 Mar 2026

Security type / class
Equity / Common Stock, $0.01 par value
Total 13F shares
43,425,726
Total reported value
$212,897,065
Holder snapshot 7 facts
Share change
+19,071,986
Put/Call ratio
38%
Reported price per share
$4.90
Number of holders
113
Value change
+$93,310,969
Number of buys
73
Number of sells
30
Security identity 1 fact
Shares outstanding
72,977,477

Security key

137404109

Report period

Q1 2026

Institutions

113

Top holders

10

CADL full security history Ownership snapshot Full 13F holder table Previous quarter: Q4 2025 Candel Therapeutics, Inc. SEC filings Candel Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of CADL - Candel Therapeutics, Inc. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Lead holder
FMR LLC
13D/G signal
FMR LLC
Evidence rows
15
Latest as of
31 Mar 2026
13F 13D/G 3/4/5 Lead comparable stake: 15% 13D/G row: FMR LLC Showing 1-6 of 15 holder rows.

Quick read

FMR LLC leads the comparable SEC ownership view at 15%.

Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Comparable ownership Top 5
FMR LLC 15%
RTW INVESTMENTS, LP 8.8%
Paul B. Manning 7.9%
ACORN BIOVENTURES, L.P. 5.2%
BAKER BROS. ADVISORS LP 5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
FMR LLC
13F 13D/G
Company
13F 13D/G
15%
from 13D/G
$46,523,790
8,234,299 shares
 — 31 Dec 2025
RTW INVESTMENTS, LP
13D/G
13D/G
8.8%
$31,788,989
6,422,018 shares
 $0 31 Mar 2026
Paul B. Manning
3/4/5 13D/G
Director
3/4/5 13D/G
7.9%
from 13D/G
$33,268,209
5,752,897 shares
mixed-class rows
 +$2,999,996 31 Mar 2026
ACORN BIOVENTURES, L.P.
13D/G
Anders Hove
13D/G
5.2%
$14,115,428
2,580,517 shares
 $0 25 Jun 2025
BAKER BROS. ADVISORS LP
13D/G
13D/G
5%
$11,882,723
2,455,108 shares
 -$2,550,075 31 Mar 2025
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
4.2%
from 13D/G
$16,168,544
2,861,689 shares
 — 31 Dec 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
113
Shares
43,425,726
Rows available
113
Investor Option Weight % Change % Reported value * Price Shares Share Change Activity Report Period

* Reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that failed the local validity check.

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders
84
Q1 2026 holders
113
Holder diff
29
Investor Q4 2025 Shares Q1 2026 Shares Share Diff Share Chg % Q4 2025 value Q1 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .